000 01347 a2200361 4500
005 20250515170850.0
264 0 _c20090522
008 200905s 0 0 eng d
022 _a1749-6632
024 7 _a10.1111/j.1749-6632.2008.03819.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDschietzig, Thomas
245 0 0 _aFirst clinical experience with intravenous recombinant human relaxin in compensated heart failure.
_h[electronic resource]
260 _bAnnals of the New York Academy of Sciences
_cApr 2009
300 _a387-92 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aDrug Administration Schedule
650 0 4 _aHeart Failure
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aInfusions, Intravenous
650 0 4 _aRecombinant Proteins
_xadministration & dosage
650 0 4 _aRelaxin
_xadministration & dosage
650 0 4 _aTreatment Outcome
700 1 _aTeichman, Sam
700 1 _aUnemori, Elaine
700 1 _aWood, Susy
700 1 _aBoehmer, Julia
700 1 _aRichter, Christoph
700 1 _aBaumann, Gert
700 1 _aStangl, Karl
773 0 _tAnnals of the New York Academy of Sciences
_gvol. 1160
_gp. 387-92
856 4 0 _uhttps://doi.org/10.1111/j.1749-6632.2008.03819.x
_zAvailable from publisher's website
999 _c18845078
_d18845078